Browse

S-Space

Browsing by Author Han, Sae-Won

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 60 of 158

Issue Date Title / Author(s) / CitationFileAltmetrics
2005-01
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
link
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2006-04
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
DOI
2006-06
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
link
2006-11
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
DOI
2007-05
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
DOI
2008-03
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Kim, Hwang-Phill; Han, Sae-Won; Kim, Sung-Hak; Im, Seock-Ah; Oh, Do-Youn; Bang, Yung-Jue; Kim, Tae-You]

Molecular Cancer Therapeutics, Vol.7 No.3, pp.607-615

link
2008-05
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
view filelink
2008-06
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
DOI
2008-07
Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment
DOI
2008-10
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
view filelink
2009-06
Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
DOI
2009-07
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
DOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2009-09
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
DOI
2010-02
Angiogenesis Imaging Using (68)Ga-RGD PET: Preliminary Report from Seoul National University Hospital
2010-03
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6
DOI
2010-03
The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer
view fileDOI
2010-03
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
DOI
2010-04
KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
DOI
2010-06
DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells

Kim, Heesun; Park, Jinah; Jung, Yeonjoo; Song, Sang-Hyun; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You

International Journal of Oncology, Vol.36 No.6, pp.1563-1572

DOI
2010-06
Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy
DOI
2010-08
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
view fileDOI
2010-09
Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study

Rhee, Jiyoung; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Journal of Gastroenterology and Hepatology, Vol.25 No.9, pp.1537-1542

DOI
2010-12
Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma
2010-12
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
DOI
2010-12
Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma
2011-01
High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
DOI
2011-03
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
view fileDOI
2011-03
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
DOI
2011-04
Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy

Kim, Ji-Won; Lee, Jeong-Ok; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

American Journal of Clinical Oncology, Vol.34 No.2, pp.125-129

DOI
2011-04
The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma
DOI
2011-05
Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
DOI
2011-05
Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
DOI
2011-05
Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab
DOI
2011-06
Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
DOI
2011-06
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
DOI
2011-07
Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins
DOI
2011-07
Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study

Shin, Dong-Yeop; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Cancer Chemotherapy and Pharmacology, Vol.68 No.1, pp.165-175

DOI
2011-09
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
DOI
2011-09
VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib
DOI
2011-10
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
DOI
2011-10
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
DOI
2011-10
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting

Lim, Kyu-Hyoung; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Cancer Chemotherapy and Pharmacology, Vol.68 No.4, pp.1017-1026

DOI
2011-12
Epigenetic-Based Therapies in Cancer Progress to Date

Song, Sang-Hyun; Han, Sae-Won; Bang, Yung-Jue

Drugs, Vol.71 No.18, pp.2391-2403

DOI
2012-01
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
DOI
2012-02
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy
DOI
2012-02
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
DOI
2012-03
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells
DOI
2012-03
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells
DOI
2012-03
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody
DOI
2012-04
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: A long-term single center experience
DOI
2012-04
The Prognostic Significance of HER2 Positivity for Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen
2012-04
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Park, Eunju; Park, Jinah; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue

International Journal of Oncology, Vol.40 No.4, pp.1259-1266

DOI
2012-05
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma
DOI
2012-07
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
view fileDOI
2012-07
Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer
DOI
2012-07
Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers
DOI
2012-07
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer
DOI
2012-07
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
view fileDOI
1 2 3

Seoul National University Library, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea TEL: 02-880-5567 Email: s-space@snu.ac.kr youtube

RSS 1.0 RSS 2.0 Atom

Hello

Browse

News About S-Space Seoul National University Library LOGIN